What is Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics is a pioneering biotechnology firm dedicated to the development of innovative stem cell therapies. At the core of its operations is the NurOwn technology platform, which utilizes specialized cells to target debilitating neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Since its inception in 2000, the company has established a strong international footprint, maintaining research and development facilities that support its advanced clinical trial programs. With Orphan Drug designations from both US and European regulatory bodies, Brainstorm Cell Therapeutics occupies a high-authority position within the regenerative medicine sector, focusing on personalized, autologous treatments that aim to modify disease progression rather than merely managing symptoms.
How much funding has Brainstorm Cell Therapeutics raised?
Brainstorm Cell Therapeutics has raised a total of $55.9M across 12 funding rounds:
Private Equity
$250K
Private Equity
$3.6M
Stock Offering
$5.7M
Multiple Rounds
$16.6M
Grant
$2.1M
Grant
$16M
Grant
$496K
Stock Offering
$10M
Debt
$150K
Stock/Share Issuance
$1M
Private Equity (2011): $250K with participation from Undisclosed
Private Equity (2011): $3.6M led by Barak Capital Underwriting
Stock Issuance/Offering (2012): $5.7M supported by Maxim Group LLC and Leader Underwriters Ltd
Share Placement (2014): $10.5M featuring Maxim Group LLC
Grant (2014): $5M backed by Brazilian Ministry of Health
Grant (2014): $1.1M with participation from Israel's Office of the Chief Scientist
Grant (2017): $2.1M led by Israel Innovation Authority
Grant (2017): $16M supported by California Institute of Regenerative Medicine
Grant (2019): $496K featuring National Multiple Sclerosis Society
Stock Issuance/Offering (2020): $10M backed by Abbhi Investments, LLC
Debt (2020): $150K with participation from PPP
Stock/Share Issuance (2026): $1M, investors not publicly disclosed
Key Investors in Brainstorm Cell Therapeutics
California Institute of Regenerative Medicine
A state-funded agency dedicated to accelerating the development of stem cell treatments and cures for chronic diseases and injuries through strategic research grants.
Israel Innovation Authority
The Innovation Authority is responsible for driving, investing in, and developing Israel's technological innovation. It supports entrepreneurs, startups, large companies, researchers, and students with innovative ideas, helping them turn visions into reality.
Maxim Group LLC
A full-service investment banking firm that provides financial advisory and capital raising services to emerging growth companies in the healthcare and biotechnology sectors.
What's next for Brainstorm Cell Therapeutics?
With the recent influx of capital, Brainstorm Cell Therapeutics is poised to scale its clinical operations and refine its NurOwn platform for broader therapeutic applications. The company's strategic roadmap likely involves the expansion of its international research capabilities and the pursuit of late-stage clinical milestones required for commercialization. By maintaining a focus on high-impact neurodegenerative research, the firm is effectively positioning itself to capture significant market share in the global biotechnology landscape. Future growth will be contingent upon the successful execution of ongoing trials and the continued support of institutional partners who recognize the long-term value of its regenerative medicine portfolio.
See full Brainstorm Cell Therapeutics company page
